Evidence map›Paper›PMID 41221560›Full record

ArticleAllergy2026

"Super-Responders" to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps.

P E Vonk, J J Otten, H B E Elzinga, R J L van der Lans, G F J P Adriaensen, L B L Benoist, D R Hoven, W J Fokkens, S Reitsma, PolyREG Consortium

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

P E VonkDepartment of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
J J OttenDepartment of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID https://orcid.org/0009-0003-5437-3005
H B E ElzingaDepartment of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0002-8576-6018
R J L van der LansDepartment of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
G F J P AdriaensenDepartment of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
L B L BenoistDepartment of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
D R HovenDepartment of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
W J FokkensDepartment of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
S ReitsmaDepartment of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.ORCID https://orcid.org/0000-0003-1734-2632
PolyREG Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDupilumab is effective in treating patients with type-2 dominant chronic rhinosinusitis with nasal polyps (T2-CRSwNP). Dosing starts at an interval of 1×/2 weeks (Q2W) with possible tapering upon disease control. Prolonging the interdose interval reduces patient burden and side effects and improves cost-effectiveness.

objectives(1) Analyze how many patients successfully reach and maintain extended tapering of at least 1×/12 weeks (Q12W), (2) evaluate differences in baseline characteristics and clinical measurements between patients who maintain disease control on ≥ Q12W ("super-responders") and patients who do not; (3) compare characteristics of "super-responders" to patients reaching Q12W but losing disease control on that dose ("excellent responders").

methodProspective cohort study including dupilumab-treated T2-CRSwNP patients with a minimum follow-up of 2.5 years.

resultsFrom a total of 198 patients, 28 (14%) were "super-responders", and 26 (13%) "excellent responders." "super-responders" had less comorbid asthma (60.7% vs. 85.9%, p < 0.001), lower baseline immunoglobulin E levels (median [Q1: Q3]: 145 [58.7; 485] vs. 313 [135.5; 746]; p = 0.007) and a shorter time since last sinus surgery (2.5 years [1; 4.8] vs. 4 years [2; 7]; p = 0.026) compared to others. No differences were observed between "excellent" and "super-responders" at baseline, nor at the start of the Q12W interval. "excellent responders" showed worsening of clinical outcomes as well as increases in T2 markers in blood between start and stop of the Q12W interval.

conclusionTapering of dupilumab to once every 12 weeks (Q12W) can be applied to super-responding patients. No clear predisposing factors were identified predicting the feasibility of extended tapering.

Indexed as

Antibodies, Monoclonal, HumanizedNasal PolypsRhinitisRhinosinusitisSinusitisAdultChronic DiseaseFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeAntibodies, Monoclonal, Humanizeddupilumabchronic rhinosinusitisdupilumabnasal polypstaperingtreatment outcome

Identifiers

PMID41221560
PMCPMC13342763

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.